Last Updated: June 22, 2025

   
     

 
Featured Articles

Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the...

HIV.gov | June 12, 2025

If Twice-Yearly Lenacapavir Could Be a HIV PrEP Game Changer, Would a Once-Yearly Version Be a HIV Epidemic Ender?

Managed Healthcare Executive | March 13, 2025

ViiV Healthcare announces new implementation study data showing zero cases of HIV with apretude, the only long-acting injectable approved for...

ViiV Healthcare | March 12, 2025

Gilead data suggests once-yearly shot of PrEP drug blocks HIV infection

STAT News | March 11, 2025

U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

Gilead | February 18, 2025

This is what happens to the body when HIV drugs are stopped for millions of people

AP | February 13, 2025

   
News Updates

‘HIV-ending’ drug could be made for just $25 per patient a year, say researchers

The Guardian | June 17, 2025

FDA Alert: Infectious Diseases Drug News Roundup

ISA | June 13, 2025

Gilead hit with FDA clinical hold for batch of HIV trials

Yahoo | June 11, 2025

Affordable HIV drug shows promise in improving vision for diabetic eye disease

News-Medical | May 27, 2205

HIV drug can improve vision in patients with common diabetes complication

NIH | May 27, 2025

Exposure to Certain HIV Drugs May Significantly Lower Risk for Alzheimer Disease

IDA | May 21, 2025

Certain HIV Meds Linked to Reduced Alzheimer’s Risk

Medscape | May 16, 2025

Expanding HIV Prevention: Overcoming Barriers and Embracing Long-Acting PrEP

Contagion Live | May 16, 2025

Alzheimer's disease could be prevented by antiviral drug already on market

Fox News | May 15, 2025

Gilead Sciences to Pay $202 Million in US Settlement Over HIV Drug Kickbacks

US News & World Report | April 29, 2025

Unhealthy Alcohol Use and HIV Preexposure Prophylaxis—Opportunities for Integrated Care

JAMA | April 25, 2025

Real-World Evidence Supports DTG+3TC for ART in Diverse HIV Populations

IDA | April 25, 2025

Gilead posts profit, says HIV prevention drug on track for mid-June

Reuters | April 24, 2025

IL plan to remove prior authorization from some HIV drugs passes the House

News 25 Illinois | April 14, 2025

Manufacturer’s plans for equitable access to twice-yearly PrEP under fire

Aidsmap | April 10, 2025

HIV testing requirements must be simplified for injectable PrEP to have a future

Aidsmap | March 21, 2025

CMV antiviral may reduce inflammation and improve immune function in people with HIV

Aidsmap | March 21, 2025

First-in-Human Study of Long-Acting Injectable HIV Nanoparticle Combination Therapy

Contagion Live | March 19, 2025

Drug Regimen For HIV Shows Non-Inferiority to Antiretroviral Therapies 

Drug Topics | March 14, 2025

Merck releases positive phase 3 data on daily oral HIV drug

MSN | March 13, 2025

What's happening with the anti-HIV program PEPFAR? It depends whom you ask

NPR | February 13, 2025

US spells out life-saving HIV treatment that can continue during aid pause

Reuters | February 1, 2025

What to Do if You Can’t Get Your HIV Medication Costs Covered

The Body | January 29, 2025

Combination of Dolutegravir, Lamivudine Effective in People Living With HIV 

American Journal of Managed Care | January 22, 2025

NIAID Study Describes Successful Treatment Regimen for Person with Multidrug-Resistant HIV

NIH | January 16, 2025

DoxyPEP Tied to Decreases in Sexually Transmitted Infections

Health Day | January 7, 2025

WHO to Develop Lenacapavir and HIV Testing Guidelines

Managed Healthcare | January 7, 2025

Twice-Yearly Lenacapavir Could Support HIV Prevention in Vulnerable Populations

JAMA | January 3, 2025

   

 
           
2019 Archives 2020 Archives 2021 Archives 2022 Archives 2023 Archives 2024 Archives